What's happening
REGENXBIO reported that its Phase III AFFINITY DUCHENNE trial met its primary endpoint with 93% of 30 patients achieving at least 10% microdystrophin expression at Week 12, with statistical significance of p<0.0001 and average expression levels of 71.1%. The data, with a cutoff date of April 16, 2026, also demonstrated a statistically significant correlation between microdystrophin expression and functional improvements measured on the NSAA scale. Chief Medical Officer Steve Pakola stated that "RGX-202 is the first gene therapy in development for Duchenne to demonstrate strong, statistically significant correlation between microdystrophin expression and functional improvement." The company plans to discuss an accelerated approval pathway with the FDA targeting a 2027 market launch.
Why it matters for markets
The positive Phase III results position RGX-202 as a potential breakthrough treatment for Duchenne muscular dystrophy, but REGENXBIO faces significant financial pressures with cash reserves of $150.5 million as of March 31, 2026, providing runway only into early 2027. The company reported a Q1 2026 net loss of $90.1 million and earnings per share of -$1.72, compared to net income of $6.1 million and EPS of $0.12 in the prior year period. R&D expenses increased to $57.3 million in Q1 2026 from $53.1 million, driven by RGX-202 clinical trial costs, while revenue dropped to $6.4 million from $89.0 million due to the absence of a $70 million Nippon Shinyaku upfront payment and lower ZOLGENSMA royalties. Despite positive clinical data, RGNX shares fell 37.43% to $6.28 on volume of 9.5 million shares, reflecting investor concerns about the earnings miss and cash burn rate ahead of potential regulatory approval.
Sectors and assets to watch
The gene therapy sector, particularly companies developing treatments for rare neuromuscular diseases, will be closely monitored following REGENXBIO's clinical success. RGNX's partnerships with Nippon Shinyaku, AbbVie, and Novartis could provide additional validation for the AAV gene delivery platform approach. The company's market capitalization of $322.3 million and 52-week trading range of $6.01-$16.19 indicate significant volatility as investors weigh clinical progress against financial sustainability concerns.
What to watch next
Key developments include REGENXBIO's upcoming FDA discussions regarding the accelerated approval pathway for RGX-202, potential partnership announcements to address the company's cash runway extending only into early 2027, and progress updates on other pipeline candidates including RGX-314 for wet AMD partnered with AbbVie and RGX-121 for Hunter syndrome.